These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 11431352)

  • 21. Cross-talk between interleukin 1beta (IL-1beta) and IL-6 signalling pathways: IL-1beta selectively inhibits IL-6-activated signal transducer and activator of transcription factor 1 (STAT1) by a proteasome-dependent mechanism.
    Shen X; Tian Z; Holtzman MJ; Gao B
    Biochem J; 2000 Dec; 352 Pt 3(Pt 3):913-9. PubMed ID: 11104703
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis.
    Jazirehi AR; Bonavida B
    Mol Cancer Ther; 2004 Jan; 3(1):71-84. PubMed ID: 14749477
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What signals are generated by anti-CD20 antibody therapy?
    Bonavida B
    Curr Hematol Malig Rep; 2006 Dec; 1(4):205-13. PubMed ID: 20425315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The nonsteroidal anti-inflammatory drug sulindac causes down-regulation of signal transducer and activator of transcription 3 in human oral squamous cell carcinoma cells.
    Nikitakis NG; Hamburger AW; Sauk JJ
    Cancer Res; 2002 Feb; 62(4):1004-7. PubMed ID: 11861373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis.
    Stolz C; Hess G; Hähnel PS; Grabellus F; Hoffarth S; Schmid KW; Schuler M
    Blood; 2008 Oct; 112(8):3312-21. PubMed ID: 18689543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs.
    Vega MI; Martinez-Paniagua M; Jazirehi AR; Huerta-Yepez S; Umezawa K; Martinez-Maza O; Bonavida B
    Leuk Lymphoma; 2008 Oct; 49(10):1982-94. PubMed ID: 18949621
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis.
    Zhao WL; Wang L; Liu YH; Yan JS; Leboeuf C; Liu YY; Wu WL; Janin A; Chen Z; Chen SJ
    Exp Hematol; 2007 Dec; 35(12):1801-11. PubMed ID: 17681667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression.
    Olejniczak SH; Hernandez-Ilizaliturri FJ; Clements JL; Czuczman MS
    Clin Cancer Res; 2008 Mar; 14(5):1550-60. PubMed ID: 18316580
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
    Shi YX; Zhang XS; Xia JC; Li YQ; Xu RH; Han WJ; Zhang JH; Guan ZZ; Jiang WQ
    Ai Zheng; 2007 Aug; 26(8):837-42. PubMed ID: 17697543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice.
    Blaskovich MA; Sun J; Cantor A; Turkson J; Jove R; Sebti SM
    Cancer Res; 2003 Mar; 63(6):1270-9. PubMed ID: 12649187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions.
    Vega MI; Huerta-Yepez S; Martinez-Paniagua M; Martinez-Miguel B; Hernandez-Pando R; González-Bonilla CR; Chinn P; Hanna N; Hariharan K; Jazirehi AR; Bonavida B
    Clin Cancer Res; 2009 Nov; 15(21):6582-94. PubMed ID: 19861448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma.
    Lewis TS; McCormick RS; Emmerton K; Lau JT; Yu SF; McEarchern JA; Grewal IS; Law CL
    Clin Cancer Res; 2011 Jul; 17(14):4672-81. PubMed ID: 21610152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo.
    Gao L; Zhang L; Hu J; Li F; Shao Y; Zhao D; Kalvakolanu DV; Kopecko DJ; Zhao X; Xu DQ
    Clin Cancer Res; 2005 Sep; 11(17):6333-41. PubMed ID: 16144938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells.
    Chen T; Wang LH; Farrar WL
    Cancer Res; 2000 Apr; 60(8):2132-5. PubMed ID: 10786674
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.
    Zerbini LF; Wang Y; Cho JY; Libermann TA
    Cancer Res; 2003 May; 63(9):2206-15. PubMed ID: 12727841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced efficacy of therapy with antisense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in scid mouse/human lymphoma xenografts.
    Smith MR; Jin F; Joshi I
    Mol Cancer Ther; 2004 Dec; 3(12):1693-9. PubMed ID: 15634664
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BCL-6 negatively regulates macrophage proliferation by suppressing autocrine IL-6 production.
    Yu RY; Wang X; Pixley FJ; Yu JJ; Dent AL; Broxmeyer HE; Stanley ER; Ye BH
    Blood; 2005 Feb; 105(4):1777-84. PubMed ID: 15507530
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression.
    Epling-Burnette PK; Liu JH; Catlett-Falcone R; Turkson J; Oshiro M; Kothapalli R; Li Y; Wang JM; Yang-Yen HF; Karras J; Jove R; Loughran TP
    J Clin Invest; 2001 Feb; 107(3):351-62. PubMed ID: 11160159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of signal transducer and activator of transcription 3 (STAT3) in gastrointestinal stromal tumors.
    Paner GP; Silberman S; Hartman G; Micetich KC; Aranha GV; Alkan S
    Anticancer Res; 2003; 23(3B):2253-60. PubMed ID: 12894500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
    Liu C; DeNardo G; Tobin E; DeNardo S
    Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.